StreetInsider.com News Articles

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

LEXINGTON, Mass.--(BUSINESS WIRE)-- Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva’s LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Thu, 18 Jun 2026 08:00:00 -0400

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive

Company seeks pipeline expansion via industry partnerships

INNOVIVA licenses XACDURO to Dr. Reddy's for select international markets

Tue, 16 Jun 2026 08:02:39 -0400

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd. for XACDURO® (sulbactam for injection; durlobactam for injection) in South and Central America, the Caribbean, Russia, and Commonwealth of Independent States countries.

Under the agreement, Dr. Reddy's will be responsible for development, regulatory, and commercialization activities in the licensed territories. Innoviva Specialty Therapeutics retains rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales. Financial terms were not disclosed.

XACDURO is approved

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Tue, 16 Jun 2026 08:00:00 -0400

Agreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals)
The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70%1,2 representing substantial unmet need

WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Tue, 16 Jun 2026 08:00:00 -0400

Agreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals)
The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70%1,2 representing substantial unmet need

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Tue, 16 Jun 2026 08:00:00 -0400

Agreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals)
The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70%1,2 representing substantial unmet need

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Tue, 16 Jun 2026 08:00:00 -0400

Agreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals)
The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70%1,2 representing substantial unmet need